FDA approves AbbVie's Emblaveo for intra-abdominal infections, stock down in regular trading, up after-hours

From Nasdaq.: 2025-02-07 19:51:26

AbbVie has received FDA approval for Emblaveo, a new antibiotic for treating complicated intra-abdominal infections. The drug is effective against various Gram-negative microorganisms and will be available for commercial use in the U.S. in the third quarter of 2025. Emblaveo was developed in collaboration with Pfizer, with AbbVie handling commercialization in the U.S. and Canada. The drug received QIDP and Fast Track designations from the FDA in 2019, providing incentives for its development and review process. AbbVie’s stock closed down in regular trading but gained slightly in after-hours trading.



Read more at Nasdaq.: AbbVie: FDA Approves Emblaveo – Metronidazole Combination For Complicated Intra-Abdominal Infections